Edition:
United States

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

6.74USD
26 May 2017
Change (% chg)

$0.08 (+1.20%)
Prev Close
$6.66
Open
$6.62
Day's High
$6.85
Day's Low
$6.44
Volume
26,913
Avg. Vol
34,925
52-wk High
$14.25
52-wk Low
$3.99

XOMA.OQ

Chart for XOMA.OQ

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.26
Market Cap(Mil.): $51.05
Shares Outstanding(Mil.): 7.59
Dividend: --
Yield (%): --

Financials

  XOMA.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -9.85 -- --
ROI: -344.48 -8.48 -5.42
ROE: -- -11.31 -4.68

BRIEF-XOMA earns $10 mln milestone payment as a licensed asset advances into clinical development

* XOMA earns $10 million milestone payment as another of its licensed assets advances into clinical development Source text for Eikon:

May 18 2017

BRIEF-Xoma Q1 loss per share $2.37

* Q1 basic and diluted net loss per share available to common shareholders of $2.37

May 09 2017

BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition

* Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition

Apr 24 2017

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

Apr 21 2017

BRIEF-Xoma presents positive data from PTH1R monoclonal antibody program

* Xoma presents positive data from PTH1R monoclonal antibody program

Apr 18 2017

BRIEF-Xoma announces full repayment of Hercules Technology Growth Capital debt obligation

* Xoma announces full repayment of hercules technology growth capital debt obligation

Mar 22 2017

BRIEF-Xoma board approved salary increases for CEO James Neal, CFO Thomas Burns on March 2, 2017

* Xoma -on March 2, 2017, board approved salary increases for James Neal, chief executive officer, and Thomas Burns, chief financial officer Source text (http://bit.ly/2mkguDP) Further company coverage:

Mar 08 2017

BRIEF-Xoma Corp to sell 1.2 mln shares to Biotechnology Value Fund

* Xoma announces pricing of $25 million registered offering of common stock and convertible preferred stock

Feb 13 2017

BRIEF-Xoma established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery

* Xoma Corp- Established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery Source text for Eikon: Further company coverage:

Jan 31 2017

More From Around the Web

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $17.93 -1.21

Earnings vs. Estimates